actoxumab
mAbexperimental
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infection. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01241552)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Toxin AINHIBITOR
tcdA inhibitor
- Clostridium difficileImmunity, passive
Clostridium difficile immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaActoxumab ↗
- ChEMBLCHEMBL2109312 ↗
- ChEMBLCHEMBL2108671 ↗
Also known as
- actoxumab
- mk-3415
- mk-3415
- mk-3415
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01513239 | Phase 3 | Feb 1, 2012 | Merck |
| NCT01241552 | Phase 3 | Oct 1, 2011 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 1 | 2011 |
1 organizations
Page 1 / 1